This perspective analyses the adverse reactions reported for mRNA-based SARS-CoV-2 vaccines in the light of infusion reactions to nanomedicines, which display similar outcomes, suggests possible mechanisms and offers a safety roadmap for vaccine developers.
- Janos Szebeni
- Gert Storm
- Marina A. Dobrovolskaia